This is a multicenter, randomized, open-label study comparing disitamab vedotin with the physician’s choice of chemotherapy, including apatinib, in patients with HER2-overexpressing (IHC3+ or 2+ regardless of ISH status) gastric cancer. The gene discussed is ERBB2; the disease is gastric cancer.